【摘要】 目的：对比分析在肺栓塞患者抗凝治疗中应用利伐沙班或华法林的临床价值。方法：抽取2018年1月-2020年9月北京市房山区第一医院74例肺栓塞患者，依据用药方案不同分为对照组和观察组。对照组患者34例，应用华法林进行抗凝治疗，观察组患者40例，应用利伐沙班抗凝治疗。比较两组治疗后的临床效果及症状消失时间。结果：观察组治疗总有效率为97.50%，高于对照组(85.29%)，差异有统计学意义(P<0.05)；观察组呼吸困难、发绀以及胸痛等症状消失时间短于对照组，差异有统计学意义(P<0.05)；两组治疗后两组患者的呼吸频率、心率、动脉血氧分压以及动脉血二氧化碳分压均较治疗前改善显著,差异有统计学意义(P<0.05)，但两组治疗后上述各指标比较，差异有统计学意义(P<0.05)；观察组不良反应率为5.00%，低于对照组(20.59%)，差异有统计学意义(P<0.05)。结论：对于肺栓塞患者应用利伐沙班的抗凝治疗效果优于华法林，前者更有利于提升治疗效果并迅速缓解症状，且安全性良好。更多还原

【Abstract】 Objective: To compare and analyze the clinical value of rivaroxaban or warfarin in anticoagulant therapy for patients with pulmonary embolism. Methods: A total of 74 patients with pulmonary embolism in the First Hospital of Fangshan District of Beijing from January 2018 to September 2020 were selected and divided into control group and observation group according to drug regimen. The control group(34 cases) received warfarin anticoagulant therapy, while the observation group(40 cases) received rivaroxaban anticoagulant therapy. The clinical effect and symptom disappearance time were compared between the two groups after treatment. Results: The total effective rate was 97.50% in the observation group, which was higher than that in the control group(85.29%), with statistically significant difference(P<0.05); The disappearance time of dyspnea, cyanosis and chest pain symptoms in the observation group was earlier than that in the control group, with statistically significant difference(P<0.05). After treatment,the respiratory rate, heart rate, arterial partial pressure of oxygen, and arterial partial pressure of carbon dioxide in the two groups were significantly improved compared with before treatment, with statistically significant difference(P<0.05), and there was significant difference in the above indexes between the two groups after treatment(P<0.05). The adverse reaction rate of observation group was 5.00%, which was lower than that of control group(20.59%), with statistically significant difference(P<0.05). Conclusion:The anticoagulant therapy effect using rivaroxaban is better than warfarin in patients with pulmonary embolism, and the former is more conducive to improving the therapeutic effect and relieving symptoms quickly, with good safety.更多还原